Latest & greatest articles for celecoxib

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on celecoxib or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on celecoxib and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for celecoxib

1. BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004) Full Text available with Trip Pro

BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004) Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy.To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk of recurrence in NMIBC patients receiving standard treatment.BOXIT (CRUK/07/004, ISRCTN84681538) is a double-blinded, phase III (...) , randomised controlled trial. Patients aged ≥18 yr with intermediate- or high-risk NMIBC were accrued across 51 UK centres between 1 November 2007 and 23 July 2012.Patients were randomised (1:1) to celecoxib 200mg twice daily or placebo for 2 yr. Patients with intermediate-risk NMIBC were recommended to receive six weekly mitomycin C instillations; high-risk NMIBC cases received six weekly bacillus Calmette-Guérin and maintenance therapy.The primary endpoint was time to disease recurrence. Analysis

2018 EvidenceUpdates

2. Celecoxib

/cachexia syndrome (CACS). 2016 16. Preoperative Administration of Celecoxib (Celebrex) is Effective for Managing Postoperative Pain In Third Molar Extractions UTCAT3052, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Preoperative Administration of Celecoxib (Celebrex) is Effective for Managing Postoperative Pain In Third Molar Extractions Clinical Question In a healthy adult, is preoperative administration of the nonsteroidal (...) anti-inflammatory drug (...) (NSAID) celecoxib (Celebrex), as compared to a placebo, an effective method for reducing postoperative pain following a third molar extraction? Clinical Bottom Line For patients requiring third molar extractions, celecoxib (Celebrex) is an effective treatment medication when compared to placebo for managing and reducing of postoperative pain. However, more uniform research methodology is required for the further evaluation of celecoxib and other NSAIDs. This result

2018 Trip Latest and Greatest

3. Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness

-operative pain following orthopedic surgery? Key Message Five randomized controlled trials were identified regarding the clinical effectiveness of pre-operative administration of gabapentin, celecoxib, or acetaminophen for patients undergoing orthopedic surgical procedures. Tags acetaminophen, orthopedic procedures, orthopedics, premedication, preoperative care, preoperative period, musculoskeletal, surgery, gabapentin, Neurontin, celecoxib, celebrex, paracetamol, Tylenol, postoperative pain, post (...) Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Published on: July 31, 2017

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT) Full Text available with Trip Pro

Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT) Chondroitin sulfate 800 mg/day (CS) pharmaceutical-grade in the management of symptomatic knee osteoarthritis consistent with the European Medicines Agency guideline.A prospective, randomised, 6-month, 3-arm, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-controlled trial assessing (...) changes in pain on a Visual Analogue Scale (VAS) and in the Lequesne Index (LI) as coprimary endpoints. Minimal-Clinically Important Improvement (MCII), Patient-Acceptable Symptoms State (PASS) were used as secondary endpoints.604 patients (knee osteoarthritis) diagnosed according to American College of Rheumalogy (ACR) criteria, recruited in five European countries and followed for 182 days. CS and celecoxib showed a greater significant reduction in pain and LI than placebo. In the intention-to-treat

2017 EvidenceUpdates

5. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. (Abstract)

Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require non-steroidal anti-inflammatory drugs (NSAIDs). We hypothesised that a cyclooxygenase-2-selective NSAID plus proton-pump inhibitor (...) randomly assigned (1:1) patients who were negative for Helicobacter pylori with a computer-generated list of random numbers to receive oral administrations of either celecoxib 100 mg twice per day plus esomeprazole 20 mg once per day or naproxen 500 mg twice per day plus esomeprazole 20 mg once per day for 18 months. All patients resumed aspirin 80 mg once per day. Both patients and investigators were masked to their treatments. The primary endpoint was recurrent upper gastrointestinal bleeding within

2017 Lancet Controlled trial quality: predicted high

6. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. Full Text available with Trip Pro

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal antiinflammatory drugs (NSAIDs), remains uncertain.Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen. The goal of the trial was to assess the noninferiority of celecoxib with regard to the primary composite (...) outcome of cardiovascular death (including hemorrhagic death), nonfatal myocardial infarction, or nonfatal stroke. Noninferiority required a hazard ratio of 1.12 or lower, as well as an upper 97.5% confidence limit of 1.33 or lower in the intention-to-treat population and of 1.40 or lower in the on-treatment population. Gastrointestinal and renal outcomes were also adjudicated.A total of 24,081 patients were randomly assigned to the celecoxib group (mean [±SD] daily dose, 209±37 mg), the naproxen

2016 NEJM Controlled trial quality: predicted high

7. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT) Full Text available with Trip Pro

Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT) Selective cyclooxygenase-2 inhibitors and conventional non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) have been associated with adverse cardiovascular (CV) effects. We compared the CV safety of switching to celecoxib vs. continuing nsNSAID therapy in a European setting.Patients aged 60 years and over (...) with osteoarthritis or rheumatoid arthritis, free from established CV disease and taking chronic prescribed nsNSAIDs, were randomized to switch to celecoxib or to continue their previous nsNSAID. The primary endpoint was hospitalization for non-fatal myocardial infarction or other biomarker positive acute coronary syndrome, non-fatal stroke or CV death analysed using a Cox model with a pre-specified non-inferiority limit of 1.4 for the hazard ratio (HR).In total, 7297 participants were randomized. During a median

2016 EvidenceUpdates

8. Preoperative Administration of Celecoxib (Celebrex) is Effective for Managing Postoperative Pain In Third Molar Extractions

Preoperative Administration of Celecoxib (Celebrex) is Effective for Managing Postoperative Pain In Third Molar Extractions UTCAT3052, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Preoperative Administration of Celecoxib (Celebrex) is Effective for Managing Postoperative Pain In Third Molar Extractions Clinical Question In a healthy adult, is preoperative administration of the nonsteroidal anti-inflammatory drug (...) (NSAID) celecoxib (Celebrex), as compared to a placebo, an effective method for reducing postoperative pain following a third molar extraction? Clinical Bottom Line For patients requiring third molar extractions, celecoxib (Celebrex) is an effective treatment medication when compared to placebo for managing and reducing of postoperative pain. However, more uniform research methodology is required for the further evaluation of celecoxib and other NSAIDs. This result is supported by a randomized

2016 UTHSCSA Dental School CAT Library

9. Effects of Combined Application of Muscle Relaxants and Celecoxib Administration After Total Knee Arthroplasty (TKA) on Early Recovery: A Randomized, Double-Blind, Controlled Study (Abstract)

Effects of Combined Application of Muscle Relaxants and Celecoxib Administration After Total Knee Arthroplasty (TKA) on Early Recovery: A Randomized, Double-Blind, Controlled Study The purpose of this study was to evaluate the effectiveness of application of muscle relaxants and celecoxib in early recovery after total knee arthroplasty (TKA). One hundred and fifty patients were randomized 1:1:1 to receive either both of muscle relaxants and celecoxib or muscle relaxants alone or placebo for 2 (...) weeks (50 patients in each group). VAS pain scores as primary efficacy, active range of motion, morphine consumption, blood loss, and postoperative complications including postoperative nausea and vomiting (PONV), extremities myasthenia and deep vein thrombosis (DVT) were determined postoperatively. Group A improved better with reduced VAS pain scores compared with another two groups. These results demonstrated that application of muscle relaxants and celecoxib into patients undergoing TKA for 2

2013 EvidenceUpdates Controlled trial quality: uncertain

10. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial Full Text available with Trip Pro

The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial Brereton N, Winn B, Akehurst (...) R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of celecoxib plus a proton pump inhibitor (PPI), compared with diclofenac plus a PPI, for patients with osteoarthritis. The authors

2013 NHS Economic Evaluation Database.

11. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial Full Text available with Trip Pro

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE--an international, open-label, randomised controlled trial--uses a novel multiarm, multistage design to assess whether the early additional use of one or two drugs (docetaxel, zoledronic acid (...) , celecoxib, zoledronic acid and docetaxel, or zoledronic acid and celecoxib) improves survival in men starting first-line, long-term hormone therapy. Here, we report the preplanned, second intermediate analysis comparing hormone therapy plus celecoxib (arm D) with hormone therapy alone (control arm A).Eligible patients were men with newly diagnosed or rapidly relapsing prostate cancer who were starting long-term hormone therapy for the first time. Hormone therapy was given as standard care in all trial

2012 EvidenceUpdates Controlled trial quality: predicted high

12. Effects of Celecoxib On Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: celecoxib, a double-edged sword for patients with angina. Full Text available with Trip Pro

Effects of Celecoxib On Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: celecoxib, a double-edged sword for patients with angina. In the previous COREA-TAXUS trial, a 6-month adjunctive use of celecoxib reduced target-lesion revascularization (TLR) without increased thrombotic risk. We aimed to confirm the effects of 3-month celecoxib in patients receiving drug-eluting stent (DES) implantation in the larger prospective, randomized trial.Patients (n (...) = 909) treated for native coronary lesions were randomized into four groups: the control or the celecoxib group with stratification by stents: paclitaxel-eluting stent (PES) or zotarolimus-eluting stent (ZES). In the celecoxib group, 200 mg of celecoxib was given twice daily for 3 months after the procedure. The primary endpoint was in-stent late loss (LL) at 6 months. In-stent LL was significantly lower in the celecoxib group than the control group (0.64 ± 0.54 vs. 0.55 ± 0.47 mm, P = 0.02

2012 EvidenceUpdates Controlled trial quality: uncertain

13. Cost-effectiveness evaluation of etoricoxib versus celecoxib and nonselective NSAIDs in the treatment of ankylosing spondylitis in Norway

Cost-effectiveness evaluation of etoricoxib versus celecoxib and nonselective NSAIDs in the treatment of ankylosing spondylitis in Norway Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 NHS Economic Evaluation Database.

14. Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer

Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Squires H, Tappenden P, Cooper K, Carroll C, Logan R, Hind D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of aspirin, celecoxib, or calcium for the prevention of colorectal cancer, with a screening programme, for the general population or those who had undergone colorectal polypectomy. Calcium chemoprevention was likely to be cost-effective after polypectomy, but the evidence was weak. Aspirin could be cost

2012 NHS Economic Evaluation Database.

15. Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness

; 1994 -; 2011 [cited 2011 Dec 1]. Available from: http://webprod3.hc-sc.gc.ca/noc-ac/start- debuter.do?lang=eng 7. Cryer B, Luo X, Assaf AR, Sands G, Mardekian J. Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis. Curr Med Res Opin. 2011 Feb;27(2):295-302. 8 . e-CPS [Internet]. Ottawa: Canadian Pharmacists Association; 2010. Celebrex®. 2010 Apr 9 [cited 2011 Nov 17]. Available from: https://www.e (...) Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs and Proton Pump Inhibitors: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness

Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs and Proton Pump Inhibitors: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence (...) be copied and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Celecoxib versus Non-selective Non-steroidal Anti-Inflammatory Drugs and Proton Pump Inhibitors: Clinical Effectiveness, Safety, and Cost-Effectiveness

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Efficacy of low-dose celecoxib in patients with acute pain (Abstract)

Efficacy of low-dose celecoxib in patients with acute pain The sore throat pain model was used to evaluate single-dose effects of celecoxib 50 and 100 mg over 6 hours in the treatment of acute pharyngeal pain. Multiple-dose effects of 50-mg bid and 100 mg followed by 50 mg over 6 to 24 hours were also evaluated. Under double-blind, randomized, placebo-controlled conditions, 269 adults with confirmed acute pharyngitis rated throat pain intensity, throat soreness, difficulty swallowing, and sore (...) throat pain relief over 24 hours. For the primary efficacy analysis (SPID2), patients receiving celecoxib 100 mg during the first 2 hours after the first dose had significantly higher mean scores than patients in the placebo group (P < .0003). Efficacy was also demonstrated for celecoxib 50 and 100 mg compared with placebo for all end points (including total pain relief, summed pain intensity differences, total reduction of throat soreness, and difficulty swallowing) at all time points after

2011 EvidenceUpdates Controlled trial quality: predicted high

18. The effects of oral ibuprofen and celecoxib in preventing pain, improving recovery outcomes and patient satisfaction after ambulatory surgery (Abstract)

The effects of oral ibuprofen and celecoxib in preventing pain, improving recovery outcomes and patient satisfaction after ambulatory surgery Nonsteroidal antiinflammatory drugs have become increasingly popular as part of multimodal analgesic regimens for pain management in the ambulatory setting. We designed this randomized, double-blind, placebo-controlled study to evaluate the effect of postoperative administration of either a nonselective nonsteroidal antiinflammatory drug (ibuprofen (...) ) or the cyclooxygenase-2 selective inhibitor (celecoxib when administered as part of a multimodal analgesic regimen) on the severity of pain, the need for rescue analgesics, and clinically relevant patient outcomes after ambulatory surgery. The primary end point was the time to resumption of normal activities of daily living.One hundred eighty patients undergoing outpatient surgery were randomly assigned to 1 of 3 treatment groups: group 1 (control) received either 2 placebo capsules (matching celecoxib) or 1

2011 EvidenceUpdates Controlled trial quality: predicted high

19. Onsenal? (Celecoxib) withdrawn from EU market

Onsenal? (Celecoxib) withdrawn from EU market Onsenal▼ (Celecoxib) withdrawn from EU market - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Onsenal▼ (Celecoxib) withdrawn from EU market Onsenal▼ (celecoxib) is no longer approved in Europe for the reduction of intestinal polyps in familial adenomatous polyposis (FAP). Published 11 December 2014 From: Therapeutic area: Contents Article date: August 2011 Onsenal▼ withdrawal Celecoxib is a non-steroidal anti-inflammatory drug (...) and cyclo-oxygenase type 2 inhibitor, which is approved for the treatment of symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Until recently, celecoxib was also authorised as the orphan drug Onsenal▼ for the reduction of intestinal polyps in familial adenomatous polyposis. At the time of approval of Onsenal▼, the licence (marketing authorisation) holder committed to do post-authorisation clinical studies. However, failure to recruit sufficient numbers into a clinical trial

2011 MHRA Drug Safety Update

20. Celecoxib for pain control in joint arthroplasty

Celecoxib for pain control in joint arthroplasty Celecoxib for pain control in joint arthroplasty Celecoxib for pain control in joint arthroplasty Mitchell MD, Fosnocht K, Williams K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Fosnocht K, Williams K. Celecoxib for pain control in joint arthroplasty. Philadelphia: Center for Evidence-based

2011 Health Technology Assessment (HTA) Database.